IDEXX Laboratories (IDXX) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $976M, up 7% year-over-year (6% organic), driven by CAG diagnostics and water segments, despite U.S. macro headwinds.

• EPS rose 11% to $2.80, with operating margin expanding by 110 basis points to 31.2%.

• Net income for Q3 was $232.8M, up from $212.2M in Q3 2023.

• High customer retention rates (over 97%) and double-digit growth in premium instrument install base supported recurring revenue growth.

• Nearly 700 preorders for the new InVue Dx analyzer were secured, with shipments beginning in Q4 and most deliveries planned for 2025.

Financial highlights

• CAG Diagnostics recurring revenue grew 7% to $783M; VetLab consumables up 11% to $329M; Water segment up 13% to $50M; LPD down 2–3% to $29M.

• Gross margin increased to 61.1% (+120–140 bps); operating margin at 31.2% (+110 bps).

• Free cash flow was $192M in Q3; net income to free cash flow conversion ratio at 91% trailing 12 months.

• $225M allocated to share repurchases in Q3; $600M in buybacks in the first nine months of 2024.

• Cash and cash equivalents at quarter-end were $308.6M.

Outlook and guidance

• Full-year 2024 organic revenue growth outlook updated to 5.3%–6%, with total revenue guidance at $3,865M–$3,890M.

• Q4 organic revenue growth expected at ~3%, with CAG diagnostic recurring revenue growth of 3.5%–4%.

• Full-year EPS guidance maintained at $10.37–$10.53, with margin improvement offsetting lower revenue outlook.

• Operating margin outlook at 28.7%–29.0%, including a 160 bps impact from litigation expense.

• Capital expenditures for 2024 projected at ~$160M.